Dendreon Probed by SEC - TheStreet

Dendreon Probed by SEC

Regulators start an informal inquiry.
Author:
Publish date:

Dendreon

(DNDN)

received a letter from the New York regional office of the

Securities and Exchange Commission

notifying the company of an informal inquiry related to its clinical trials for Provenge and the attempt to get the prostate cancer vaccine cleared in the U.S.

The SEC's letter, dated July 3 and received July 9, says the investigation shouldn't be construed as an indication by the SEC or its staff that a violation of federal securities laws has occurred.

Dendreon plans to cooperate with the SEC staff and respond to a request for information. The company doesn't intend to comment on any aspect of the inquiry or possible outcomes until the probe has been completed.